Document is current

Article History

Received: 28 May 2025

Accepted: 13 February 2026

First Online: 28 February 2026

Declarations

:

: The national competent ethics committees approved the study protocols (Austrian Ethics Committee registration number 26–210 ex 13/14), and the study was conducted following the International Society for Pharmacoepidemiology guidelines for Good Pharmacoepidemiology Practice, the ethical principles of the Declaration of Helsinki, and all standing regulations of each participating country. Signed informed consent was obtained from all patients.

: Not applicable.

: E.W. and S.B. are employees of the Medical Department of A. Menarini Pharma GmbH. P.S. and I.K. are employees of the Medical Department of Menarini Hellas SA. K.K. has received honoraria for presentations and/or consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, ELPEN, GSK, Guidotti, Menarini, Pfizer, Sanofi, Specialty Therapeutics. His department has received funding and/or grants from AstraZeneca, Boehringer Ingelheim, Chiesi, ELPEN, GSK, Menarini. He was employed by AstraZeneca as Global Medical Head Respiratory Biologics. He is a member of the GOLD Assembly. H.O. has received honoraria for presentation and/or consultancy fees from Aerovate, AOP, Astra Zeneca, Bayer, Boehringer Ingelheim, Chiesi, Ferrer, Janssen, Liquidia, Menarini, MSD, and Sanofi. L.L., D.M.K. and F.M. are employees of the Medical Department of A. Menarini Farmaceutica internazionale srl. The authors report no other conflicts of interest in this publication.